Axsome Therapeutics, Inc.

AXSM

US05464T1043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-13 pm EDT			5-day change	1st Jan Change
93.67 ^USD	+2.09%		+0.52%	+17.69%

Sep. 12	Axsome Therapeutics Insider Sold Shares Worth $1,005,871, According to a Recent SEC Filing	MT
Sep. 04	Transcript : Axsome Therapeutics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

September 04, 2024 at 07:00 am EDT

Axsome Therapeutics, Inc. announced that the U.S. Food and Drug Administration has acknowledged the resubmission of the Company?s New Drug Application for AXS-07 for the acute treatment of migraine. The FDA designated the resubmission as a Class 2 resubmission and set a Prescription Drug User Fee Act action goal date of January 31, 2025.

Latest news about Axsome Therapeutics, Inc.

Axsome Therapeutics Insider Sold Shares Worth $1,005,871, According to a Recent SEC Filing	Sep. 12	MT
Transcript : Axsome Therapeutics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM	Sep. 04
Axsome Therapeutics Says FDA Accepts Potential Migraine Treatment Resubmission	Sep. 04	MT
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine	Sep. 04	CI
Wells Fargo Initiates Axsome Therapeutics at Overweight With $140 Price Target	Sep. 03	MT
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi Patent Litigation With Sandoz	Aug. 21	MT
Axsome Therapeutics Insider Sold Shares Worth $4,022,488, According to a Recent SEC Filing	Aug. 12	MT
UBS Cuts Price Target on Axsome Therapeutics to $105 From $107, Maintains Buy Rating	Aug. 06	MT
BofA Securities Upgrades Axsome Therapeutics to Buy From Neutral, Raises Price Target to $106 From $95	Aug. 06	MT
BofA Securities Upgrades Axsome Therapeutics to Buy From Neutral	Aug. 06	MT
RBC Trims Price Target on Axsome Therapeutics to $130 From $131, Keeps Outperform Rating	Aug. 06	MT
Transcript : Axsome Therapeutics, Inc., Q2 2024 Earnings Call, Aug 05, 2024	Aug. 05
Axsome Therapeutics Q2 Loss Widens, Revenue Rises; Shares Fall Pre-Bell	Aug. 05	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Reports Q2 Loss $-1.67, vs. Street Est of $-1.33	Aug. 05	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Reports Q2 Revenue $87.2M, vs. Street Est of $86.9M	Aug. 05	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Reports Q2 Loss $-1.67Per Share, vs. Street Est of Loss $-1.33 Per Share	Aug. 05	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 05	CI
Needham Starts Axsome Therapeutics With Buy Rating, $130 Price Target	Jul. 22	MT
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating	Jul. 09	MT
Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories	Jun. 05	MT
RBC Raises Price Target on Axsome Therapeutics to $130 From $127, Keeps Outperform Rating	Jun. 05	MT
Transcript : Axsome Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM	May. 16
Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating	May. 08	MT
Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating	May. 07	MT
Transcript : Axsome Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06

Chart Axsome Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Employees

589

Sector

Pharmaceuticals

Calendar

2024-09-18 - Cantor Global Healthcare Conference

More about the company